| scholarly article | Q13442814 |
| P50 | author | Jeffrey Miller | Q42613275 |
| P2093 | author name string | Mahasweta Girgenrath | |
| Christine A Kostek | |||
| Janice A Dominov | |||
| P2860 | cites work | Immortalization of mouse myogenic cells can occur without loss of p16INK4a, p19ARF, or p53 and is accelerated by inactivation of Bax | Q24791108 |
| Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency | Q28141536 | ||
| Merosin and congenital muscular dystrophy | Q28145060 | ||
| Bax-deficient mice with lymphoid hyperplasia and male germ cell death | Q28589360 | ||
| Pro- and anti-apoptotic members of the Bcl-2 family in skeletal muscle: a distinct role for Bcl-2 in later stages of myogenesis | Q28591162 | ||
| Characterization of ARC, apoptosis repressor interacting with CARD, in normal and dystrophin-deficient skeletal muscle | Q28594773 | ||
| An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. | Q34091913 | ||
| Pharmacological strategies for muscular dystrophy | Q35128906 | ||
| Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. | Q35798201 | ||
| Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. | Q35834262 | ||
| A novel myoblast enhancer element mediates MyoD transcription | Q36704745 | ||
| Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models | Q37384623 | ||
| Schwann cell myelination occurred without basal lamina formation in laminin alpha2 chain-null mutant (dy3K/dy3K) mice | Q42507557 | ||
| Complement 3 deficiency and oral prednisolone improve strength and prolong survival of laminin alpha2-deficient mice | Q43405959 | ||
| Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice | Q43977943 | ||
| Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. | Q44661085 | ||
| Genetic Models in Applied Physiology. Merosin deficiency leads to alterations in passive and active skeletal muscle mechanics | Q47927446 | ||
| Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol | Q47995990 | ||
| High protein diet has beneficial effects in murine muscular dystrophy | Q49178880 | ||
| The regulation of MyoD gene expression: conserved elements mediate expression in embryonic axial muscle. | Q52205830 | ||
| Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. | Q52527453 | ||
| Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin α2-deficient mice | Q57270383 | ||
| Inhibition of ICE slows ALS in mice | Q59081638 | ||
| Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis | Q73520806 | ||
| IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice | Q73739705 | ||
| Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy | Q73918582 | ||
| Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for alpha2 chain of laminin) | Q77894566 | ||
| Activation of caspase-3 apoptotic pathways in skeletal muscle fibers in laminin alpha2-deficient mice | Q77920398 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | congenital disorder | Q727096 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 1635-1639 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy | |
| P478 | volume | 114 |
| Q95840621 | A Family of Laminin α2 Chain-Deficient Mouse Mutants: Advancing the Research on LAMA2-CMD |
| Q49571085 | Aberrant Caspase Activation in Laminin-α2-Deficient Human Myogenic Cells is Mediated by p53 and Sirtuin Activity. |
| Q38644294 | Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD |
| Q54210538 | Amelioration of Muscle and Nerve Pathology in LAMA2 Muscular Dystrophy by AAV9-Mini-Agrin. |
| Q39559269 | Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A). |
| Q42114204 | Anti-apoptotic Effects of Human Wharton's Jelly-derived Mesenchymal Stem Cells on Skeletal Muscle Cells Mediated via Secretion of XCL1 |
| Q24602606 | Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice |
| Q28511114 | Apoptosis repressor with a CARD domain (ARC) restrains Bax-mediated pathogenesis in dystrophic skeletal muscle |
| Q54560138 | Autophagy is increased in laminin α2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A. |
| Q28585764 | BAG3 deficiency results in fulminant myopathy and early lethality |
| Q37598031 | Basement membranes and human disease. |
| Q33995531 | Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy |
| Q41854808 | Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells |
| Q37085050 | Biology of the striated muscle dystrophin-glycoprotein complex |
| Q37944530 | Cell-matrix interactions in muscle disease |
| Q37738318 | Congenital muscular dystrophies: toward molecular therapeutic interventions |
| Q45865539 | Congenital muscular dystrophy: mini-agrin delivers in mice |
| Q91906240 | Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy |
| Q35049698 | Deficiency of the Bax gene attenuates denervation-induced apoptosis |
| Q37764976 | Direct effects of the pathogenic mutation on satellite cell function in muscular dystrophy |
| Q24791491 | Diseased muscles that lack dystrophin or laminin-alpha2 have altered compositions and proliferation of mononuclear cell populations |
| Q27323309 | Distinct roles for laminin globular domains in laminin alpha1 chain mediated rescue of murine laminin alpha2 chain deficiency |
| Q42700190 | Do's and don'ts in the preparation of muscle cryosections for histological analysis |
| Q34415166 | Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice |
| Q42754638 | Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy |
| Q42127428 | Dystroglycan and dystroglycanopathies: report of the 187th ENMC Workshop 11-13 November 2011, Naarden, The Netherlands |
| Q28589201 | Effects of Bax gene deletion on muscle and motoneuron degeneration in a sexually dimorphic neuromuscular system |
| Q30512833 | Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters. |
| Q37864433 | Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy |
| Q37531866 | Immortalized myogenic cells from congenital muscular dystrophy type1A patients recapitulate aberrant caspase activation in pathogenesis: a new tool for MDC1A research |
| Q33787898 | Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy |
| Q37411771 | Ku70 regulates Bax-mediated pathogenesis in laminin-alpha2-deficient human muscle cells and mouse models of congenital muscular dystrophy. |
| Q94544460 | LAMA2 Neuropathies: Human Findings and Pathomechanisms From Mouse Models |
| Q40300149 | Laminin alpha1 chain improves laminin alpha2 chain deficient peripheral neuropathy |
| Q33281763 | Laminin isoforms in development and disease |
| Q41086617 | Laminin {alpha}1 chain corrects male infertility caused by absence of laminin {alpha}2 chain |
| Q41881081 | Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy |
| Q35952091 | Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy |
| Q36531788 | Laminin-211 in skeletal muscle function |
| Q38815433 | Laminin: loss-of-function studies. |
| Q35274694 | Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A. |
| Q36118063 | Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages |
| Q28548194 | Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A) |
| Q36027867 | Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A. |
| Q34994784 | Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A |
| Q34769964 | Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy |
| Q34597868 | Over-expression of BCL2 rescues muscle weakness in a mouse model of oculopharyngeal muscular dystrophy |
| Q34285775 | P38α MAPK underlies muscular dystrophy and myofiber death through a Bax-dependent mechanism |
| Q37091285 | Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy |
| Q35030852 | Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-α2-deficient mouse model of congenital muscular dystrophy. |
| Q30841381 | Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy |
| Q35440708 | Proinflammatory Signals and the Loss of Lymphatic Vessel Hyaluronan Receptor-1 (LYVE-1) in the Early Pathogenesis of Laminin Alpha2-deficient Skeletal Muscle |
| Q54401460 | Proteasome inhibition improves the muscle of laminin α2 chain-deficient mice. |
| Q35201194 | Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation, and increased expression of extracellular matrix proteins in laminin α2 chain-deficient muscle |
| Q22001192 | Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies |
| Q34426456 | Soleus muscle in glycosylation-deficient muscular dystrophy is protected from contraction-induced injury |
| Q36842039 | The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy |
| Q37555710 | The collagen VI-related myopathies: muscle meets its matrix |
| Q37946876 | The dystrophin-glycoprotein complex in the prevention of muscle damage |
| Q36592193 | The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis |
| Q37021293 | The role of cell death in sexually dimorphic muscle development: male-specific muscles are retained in female bax/bak knockout mice |
| Q24681141 | The zebrafish candyfloss mutant implicates extracellular matrix adhesion failure in laminin alpha2-deficient congenital muscular dystrophy |
| Q39864265 | Transgenic overexpression of laminin alpha1 chain in laminin alpha2 chain-deficient mice rescues the disease throughout the lifespan |
| Q42489627 | Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A. |
| Q37138490 | Wasting mechanisms in muscular dystrophy. |
| Q46820379 | Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. |
Search more.